Prof. Yupei Zhao 赵玉沛
Oncology
Peking Union Medical College Hospital, Beijing
Public profile Compiled from public sources. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions
- Academician, Chinese Academy of Sciences
- Honorary President, Peking Union Medical College Hospital
Checked against a public report (2026-09). Positions change; the hospital's website is the final word.
Clinical focus: Surgical and comprehensive treatment of pancreatic diseases, including radical resection for pancreatic cancer, management of pancreatic neuroendocrine tumors, and surgical treatment for chronic pancreatitis. Care for biliary and ampullary tumors, with multidisciplinary consultations for complex abdominal tumors.
Conditions and procedures: Pancreatic cancer, Pancreatic neuroendocrine tumors, Chronic pancreatitis, Biliary tumors, Ampullary tumors, Complex abdominal tumors
Compiled from public information; not confirmed with the hospital or the doctor.
Name order: in Chinese the family name comes first (Zhao Yupei). Papers usually list the name as Yupei Zhao.
Selected publications
154 first- or senior-author papers on PubMed where the author's own affiliation is this hospital (154 since 2016), counted among the 200 most recent matching papers. Most recent:
- Cancer Lett, 2026 (senior author): Tumor-nervous system crosstalk in PDAC: Current landscape, challenges, and future directions. PubMed 42982411
- Surg Endosc, 2026 (senior author): Short-term outcomes of robotic-assisted distal pancreatectomy using domestic KangDuo Surgical Robot-2000 System versus Da Vinci Xi system: a two-center prospective observational cohort study. PubMed 42637946
- Cancer Lett, 2026 (senior author): TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated DNA damage repair and IRS2 expression in pancreatic cancer. PubMed 42431391
- Sci Bull (Beijing), 2026 (senior author): AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes. PubMed 42321044
- Cancer Lett, 2026 (senior author): Spatial multi-omics defines cancer-associated fibroblasts subtype gradients driving metabolic support and immune remodeling in pancreatic ductal adenocarcinoma. PubMed 42144098
- Cancer Lett, 2026 (senior author): Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. PubMed 42081963
- Gut, 2026 (senior author): Neutrophil extracellular traps induced by tumour-derived NGAL reprogram CAF subtypes via ITGA5 to promote tumour progression in pancreatic cancer. PubMed 42463423
- Signal Transduct Target Ther, 2026 (senior author): Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. PubMed 42324245
Each paper was checked automatically: the author listed with this name must give this hospital as their affiliation. See the full PubMed search.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and recommend a treatment plan.
Get a specialist opinion